EHA-EMN Evidence-Based Guidelines for diagnosis, treatment and follow-up of patients with multiple myeloma

EHA–EMN Evidence-Based Guidelines for the diagnosis, treatment, and follow-up of multiple myeloma (MM) patients have been updated, incorporating advancements from January 2021 to May 2025. It details updated criteria for disease staging and prognosis, including the R2-ISS system and novel biomarkers like minimal residual disease. The guidelines provide key treatment recommendations for newly diagnosed MM (transplant-eligible and ineligible patients), relapsed and/or refractory MM, and smoldering multiple myeloma, reflecting recent drug approvals and clinical trial results, and comprehensive supportive care guidelines for common MM complications and adverse events.